EUVIMEDSkopri EUVIMED
Übersichtsarbeit

Recent advances of benzimidazole as anticancer agents

Sneha Venugopal, Balwinder Kaur, Anil Verma, Pankaj Wadhwa, Muskan Magan, Sharwan Hudda, Violina Kakoty

Chemical Biology & Drug Design · 2023-08 · 102 (2) · 357-376

DOI: 10.1111/cbdd.14236 ↗

At a glance

Übersichtsarbeit in Chemical Biology & Drug Design, published online on 2023-04-03. Written by Sneha Venugopal and 6 co-authors. Institution: Department of Pharmaceutical Sciences, School of Pharmacy, Lovely Professional University, Punjab, India. Major MEDLINE topics: Antineoplastic Agents. Cited 65 times so far (Crossref); 91 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Cancer is the second leading cause of death globally, with 9.6 million deaths yearly. As a life‐threatening disease, it necessitates the emergence of new therapies. Resistance to current chemotherapies drives scientists to develop new medications that will eventually be accessible. Because heterocycles are so common in biological substances, compounds play a big part in the variety of medications that have been developed. The “Master Key” is the benzimidazole nucleus, which consists of a six‐membered benzene ring fused with a five‐membered imidazole/imidazoline ring, which is an azapyrrole. One of the five‐membered aromatic nitrogen heterocycles identified in American therapies that have been approved by the Food and Drug Administration (FDA). Our results show that benzimidazole's broad therapeutic spectrum is due to its structural isosteres with purine, which improves hydrogen bonding, electrostatic interactions with topoisomerase complexes, intercalation with DNA, and other functions. It also enhances protein and nucleic acid inhibition, tubulin microtubule degeneration, apoptosis, DNA fragmentation, and other functions. Additionally, readers for designing the more recent benzimidazole analogues as prospective cancer treatments.

Subjects

MeSH terms (MEDLINE)

Antineoplastic AgentsPharmaceutical PreparationsBenzimidazolesDNA

Author keywords

PARPandrogen receptorbenzimidazolecancer targetstopoisomerasetubulin inhibitorstyrosine kinase

Substances

Antineoplastic AgentsPharmaceutical PreparationsBenzimidazolesDNA

Authors and institutions

  • Department of Pharmaceutical Sciences, School of Pharmacy, Lovely Professional University, Punjab, India.

Cite

APA

Venugopal, S., Kaur, B., Verma, A., Wadhwa, P., Magan, M., Hudda, S., & Kakoty, V. (2023). Recent advances of benzimidazole as anticancer agents. Chemical Biology & Drug Design, 102(2), 357-376. https://doi.org/10.1111/cbdd.14236

Vancouver

Venugopal S, Kaur B, Verma A, Wadhwa P, Magan M, Hudda S, et al. Recent advances of benzimidazole as anticancer agents. Chemical Biology & Drug Design. 2023;102(2):357-376. doi:10.1111/cbdd.14236

BibTeX
@article{Venugopal2023,
  author = {Venugopal, Sneha and Kaur, Balwinder and Verma, Anil and Wadhwa, Pankaj and Magan, Muskan and Hudda, Sharwan and Kakoty, Violina},
  title = {Recent advances of benzimidazole as anticancer agents},
  journal = {Chemical Biology & Drug Design},
  year = {2023},
  volume = {102},
  number = {2},
  pages = {357--376},
  doi = {10.1111/cbdd.14236}
}
Start for free →